Objective To identify risk factors for retinopathy in patients with hypertensive disorders of pregnancy (HDP) and develop a predictive nomogram model. Methods A total of 667 patients with PIH treated at our hospital between December 2020 and December 2025 were retrospectively enrolled based on M. Kendall sample size estimation. Patients were randomly assigned to a development cohort ( n = 400) and an internal validation cohort ( n = 267) in a 6:4 ratio. According to the occurrence of retinopathy, the modeling group was further divided into a retinopathy group ( n = 112) and a non-retinopathy group ( n = 288). Additionally, 200 PIH patients from Xunwu County People's Hospital (January 2021 to December 2024) were included as an external validation cohort. LASSO regression was used to screen potential predictors, followed by multivariate logistic regression to identify independent risk factors. A nomogram prediction model was constructed. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results Among the 400 patients in the modeling group, 112 developed retinopathy, with an incidence of 28.0%. Eight potential predictors were identified by LASSO regression. Multivariate analysis revealed that HDP onset 28 weeks (OR = 7.027), disease duration 3 weeks (OR = 11.548), proteinuria (+++) (OR = 14.535), hematocrit 0.35 (OR = 16.733), and systolic blood pressure (OR = 1.143) were independent risk factors (all P 0.05). Pre-pregnancy BMI (OR = 0.308), albumin (OR = 0.654), and platelet count (OR = 0.961) were independent protective factors ( P 0.05). The nomogram demonstrated good calibration in the training, internal validation, and external validation cohorts. The AUC values were 0.948 (95% CI: 0.925–0.970), 0.921 (95% CI: 0.881–0.962), and 0.907 (95% CI: 0.842–0.972), respectively. DCA showed favorable net clinical benefit across a wide range of threshold probabilities. Conclusion The nomogram based on clinical and laboratory indicators demonstrated good discrimination and calibration in internal and external validation of retinopathy risk in PIH patients, with good clinical applicability.
Gan et al. (Wed,) studied this question.